CSL Limited: Hyperkalemia trials

The registry lists 11 Hyperkalemia studies with CSL Limited as lead sponsor. 1 are open to participants now and 8 have results posted.

Phase 2 6Phase 3 3Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium LevelsRecruitingNCT05766839Phase 2
• Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)CompletedNCT03888066Phase 3Results posted
• Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and HyperkalemiaTerminatedNCT03087058Phase 2Results posted
• Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney DiseaseCompletedNCT03071263Phase 2Results posted
• Patiromer With or Without Food for the Treatment of HyperkalemiaCompletedNCT02694744Phase 4Results posted
• An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on HemodialysisTerminatedNCT02033317Phase 2Results posted
• A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)CompletedNCT01810939Phase 3Results posted
• Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)CompletedNCT01371747Phase 2Results posted
• Evaluation of Patiromer in Heart Failure PatientsCompletedNCT00868439Phase 2Results posted
• Trial Evaluating the Efficacy and Safety of Patiromer in Chinese SubjectsCompletedNCT05136664Phase 3
• Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of HyperkalaemiaCompletedNCT04864795